Delek US (DK) director sells under 10b5-1 near $38; 168,161 D
Delek US Holdings (DK): Director Ezra Uzi Yemin reported open‑market sales made pursuant to a Rule 10b5‑1 plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Delek US Holdings (DK): Director Ezra Uzi Yemin reported open‑market sales made pursuant to a Rule 10b5‑1 plan. On 10/23/2025, he sold 7,249 shares of common stock at a weighted average price of $38.04 (direct) and 26,578 shares at $38.04 (indirect via Yemin Investments, LP). On 10/24/2025, he sold 20,982 shares at $38.16 (direct) and 76,927 shares at $38.16 (indirect). On 10/27/2025, he sold 188 shares at $38.01 (direct) and 688 shares at $38.01 (indirect).
Following these transactions, beneficial ownership stood at 168,161.047 shares direct and 728,952 shares indirect.
Insights
Director Ezra Uzi Yemin sold 132,612 DK shares under a Rule 10b5-1 plan; sizable but preplanned, with substantial holdings remaining.
The filing reports multiple open-market sales by **Ezra Uzi Yemin (Director)** on
Post-transaction, reported beneficial ownership stands at 168,161.047 shares held directly and 728,952 shares held indirectly via **Yemin Investments, LP**. The Rule 10b5-1 designation indicates prearranged trades, and the filer offers to provide per-trade details within the stated price ranges upon request, which supports transparency on execution.
Key items to watch: any continuation of scheduled sales under this plan and subsequent Form 4s showing changes to direct or LP-held balances. The most recent activity date is
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 188 | $38.01 | $7K |
| Sale | Common Stock | 688 | $38.01 | $26K |
| Sale | Common Stock | 20,982 | $38.16 | $801K |
| Sale | Common Stock | 76,927 | $38.16 | $2.94M |
| Sale | Common Stock | 7,249 | $38.04 | $276K |
| Sale | Common Stock | 26,578 | $38.04 | $1.01M |
Footnotes (4)
- F1. This transaction was pursuant to a Rule 10b5-1 plan.
- F2. The price reflects the weighted average sale price of multiple transactions ranging from $38.00 to $38.26 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.
- F3. The price reflects the weighted average sale price of multiple transactions ranging from $38.00 to $38.45 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.
- F4. The price reflects the weighted average sale price of multiple transactions ranging from $38.00 to $38.09 per share. Upon the written request of the SEC, the issuer or a security holder of the issuer, the reporting person agrees to provide the number of shares sold at each sale price.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did DK’s director report in this Form 4?
When did the transactions occur for DK (Delek US Holdings)?
What were the DK sales on 10/24/2025 and pricing?
What were the DK sales on 10/27/2025 and pricing?
What is the director’s DK beneficial ownership after these sales?
Were these DK trades under a Rule 10b5‑1 plan?
AI-generated analysis. How Rhea-AI works. Not financial advice.